Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis-Reference-Cited by-同舟云学术

Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis

Published:2017-09 Issue: Volume:55 Page:139-152
ISSN:0167-6296
Container-title:Journal of Health Economics
language:en
Short-container-title:Journal of Health Economics

Author:

Hernández-Alava Mónica^ORCID,Pudney Stephen

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference37 articles.

1. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population;Agborsangaya;Health Qual. Life Outcomes,2014

2. An EQ-5D-5L value set based on Uruguayan population preferences?;Augustovski;Qual. Life Res.,2016

3. Vines – a new graphical model for dependent random variables;Bedford;Ann. Stat.,2002

4. Improving cross-sector comparisons: going beyond the health-related QALY;Brazier;Appl. Health Econ. Health Policy,2015

5. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures?;Brazier;Eur. J. Health Economics,2010

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical and cost effectiveness of internet-delivered self-help Acceptance and Commitment Therapy for family carers of people with dementia (iACT4CARERS): Study protocol for a randomised controlled trial with ethnically diverse family carers;Contemporary Clinical Trials;2024-11

2. Psychometric Performance of the EQ Health and Wellbeing Short in a United Kingdom Population Sample;Value in Health;2024-09

4. Use of removable support boot versus cast for early mobilisation after ankle fracture surgery: cost-effectiveness analysis and qualitative findings of the Ankle Recovery Trial (ART);BMJ Open;2024-01

5. Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective;PharmacoEconomics;2023-10-05